The Evaluation of Angiotensin-Converting Enzyme Inhibitors in Renal Elimination with Selected Molecular Descriptors

1. Lemke TL, Williams DA (eds). The Foye’s Principles of Medicinal Chemistry 6 th ed. Wolters Kluwer, Lippincott Williams & Wilkins, Philadelphia, 2013.Search in Google Scholar

2. Giverhaug T, Falck A, Eriksen BO. Effectiveness of anti-hypertensive treatment in chronic renal failure: to what extent and with which drugs do patients treated by nephrologists achieve the recommended blood pressure? J Hum Hypertens 2004; 18: 649-54.10.1038/sj.jhh.1001705Search in Google Scholar

3. Piepho RW. Overview of the angiotensin-convering-enzime inhibitors. Am J HealthSystem Pharm 2000; 57: 3-7.10.1093/ajhp/57.suppl_1.S3Search in Google Scholar

4. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang and Dale’s Farmacology 8 th, Elsevier, Churchill Livingstone, 2012.Search in Google Scholar

5. Ruster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol 2006; 17: 2985-2991.10.1681/ASN.2006040356Search in Google Scholar

6. Razzetti R, Acerbi D. Pharmacokinetic and pharmacologic properties of delapril, a lipophilic nonsulfhydryl angiotensin converting enzyme inhibitor. Am J Cardiol 1995; 75: 7F-12F.10.1016/S0002-9149(99)80508-6Search in Google Scholar

7. Saruta T, Nishikawa K. Characteristics of a new angiotensin converting enzyme inhibitor: delapril. Am J Hipertens 1991; 2: 23S-28S.10.1093/ajh/4.1.23SSearch in Google Scholar

8. Miyazaki M, Kawamoto T, Okunishi H. Vascular affinity of trandolapril. Am J Hiperten 1995; 8: 63S-67S.10.1016/0895-7061(95)00191-3Search in Google Scholar

9. Conen H, Brunner HR. Pharmacologic profile of trandolapril a new angiotensin converting enzyme inhibitor. Am Hearth J 1993; 125: 1525-1531.10.1016/0002-8703(93)90450-NSearch in Google Scholar

10. Ranadive SA, Chen AX, Serajuddin TM. Relative lipophilicities and structural – pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors. Pharm Research 1992; 9: 1480-1486. 1210.1023/A:1015823315983Search in Google Scholar

11. Abbara Ch, Aymard G, Hinh S, Diquet B. Simultaneous determination of quinapril and its active metabolite quinaprilat in human plasma using high-performance liquid chromatography with ultraviolet detection. J Chromatogr B 2002; 766: 199-207.10.1016/S0378-4347(01)00474-1Search in Google Scholar

12. Gumieniczek A, Hopkala H. High performance chromatographic assay of quinapril in tablets. Pharm Acta Helv 1998; 73: 183-185.10.1016/S0031-6865(98)00019-3Search in Google Scholar

13. Bouabdallah S, Trabelsi H, Bouzouita K, Sabbah S. Reversed-phase chromatography of lisinopril conformers. J Biochem Biophys Methods 2002; 54: 391-405.10.1016/S0165-022X(02)00140-9Search in Google Scholar

14. El-Gindy A, Ashour A, Fattah LA, Shabana MM. Spectrophotometric and HPTLC densitometric determination of lisinopril and hydrochlorothiazide in binary mixtures. J Pharm Biomed Anal 2001; 25: 923-931.10.1016/S0731-7085(01)00382-XSearch in Google Scholar

15. Prieto JA, Akesolo U, Jimenez RM, Alonso RM. Capillary zone electrophoresis applied to the determination of the angiotensin-converting enzyme inhibitor cilazapril and its active metabolite in pharmaceuticals and urine. J Chromatogr A 2001; 916: 279-288.10.1016/S0021-9673(01)00565-9Search in Google Scholar

16. El-Gindy A, Ashour A, Abdel Fattah L, Shabana MM. Spectrophotometric, spectrofluorimetric and LC determination of lisinopril. J Pharm Biomed Anal 2001; 25: 913-922.10.1016/S0731-7085(01)00376-4Search in Google Scholar

17. Bonazzi D, Gotti R, Andrisano V, Cavrini V. Analysis of ACE inhibitors in pharmaceutical dosage forms by derivative UV spectroscopy and liquid chromatography (HPLC) J Pharm Biomed Anal 1997; 16: 431-438.10.1016/S0731-7085(97)00075-7Search in Google Scholar

18. Odovic JV, Stojimirovic BB, Aleksic MB, Milojković-Opsenica DM, Tešic Ž.Lj. Examination of the hydrophobicity of ACE inhibitors and their active metabolites by salting-out thin-layer chromatography. J Planar Chromat 2005; 18: 98-103. 1310.1556/JPC.18.2005.2.2Search in Google Scholar

19. Odovic J, Stojimirovic B, Aleksic M, Milojkovic-Opsenica D, Tesic Z. Reversedphase thin-layer chromatography of some angiotensin converting enzyme (ACE) inhibitors and their active metabolites. J Serb Chem Soc 2006; 71(6): 621-628.10.2298/JSC0606621OSearch in Google Scholar

20. Odovic J, Aleksic M, Stojimirovic B, Milojkovic-Opsenica D, Tesic Z. Normal-phase thin-layer chromatography of some ACE inhibitors and their metabolites. J Serb Chem Soc 2009; 74(6): 677-688.10.2298/JSC0906677OSearch in Google Scholar

21. Odovic J, Trbojevic-Stankovic J. Correlation between Angiotensin-converting enzyme inhibitors lipophilicity and protein binding data. Acta Medica Medianae 2012; 51(4): 13-18.Search in Google Scholar

22. Odovic JV, Markovic, BD, Injac RD, Vladimirov SM Karljikovic-Rajic KD. Correlation between ultra-high performance liquid chromatography–tandem mass spectrometry and reversed-phase thin-layer chromatography hydrophobicity data for evaluation of angiotensin-converting enzyme inhibitors absorption. J Chromatogr A 2012; 1258: 94-100.10.1016/j.chroma.2012.08.038Search in Google Scholar

23. Molinspiration software or free molecular property calculation services. Available from URL: www.molinspiration.comSearch in Google Scholar

24. Tetko IV. Virtual Computational Chemistry Laboratory. Available from URL: www.vcclab.orgSearch in Google Scholar

25. DrugBank. Available from URL: www.drugbank.caSearch in Google Scholar

26. Di L, Kernsy EH. Profiling drug - like properties in discovery research. Curr Opin Chem Biol 2003; 7:402-408.10.1016/S1367-5931(03)00055-3Search in Google Scholar

27. Remko M, Swart M, Matthias Bickelhaupt F. Theoretical study of structure, pKa, lipophilicity, solubility, absorption and polar surface area of some centrally acting antihypertensives. Bioorg Med Chem 2006; 14: 1715-1728. 1410.1016/j.bmc.2005.10.02016263295Search in Google Scholar

28. Remko M. Acidity, lipophilicity, solubility, absorption, and polar surface area of some ACE inhibitors. Chem Pap 2007; 61(2): 133-141.10.2478/s11696-007-0010-ySearch in Google Scholar

29. Zhao YH, Le J, Abraham MH, Hersey A, Eddershaw PJ, Luscombe CN, Boutina D, Beck G, Sherbone B, Cooper I, Platts JA. Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors. J Pharm Sci 2001; 90: 749-784.10.1002/jps.103111357178Search in Google Scholar

30. Hellstern A, Hildebrand M, Humpel M, Hellenbrecht D, Saller R, Madetzki C. Minimal biliary excretion and enterohepatic recirculation of lormetazepam in man as investigated by a new nasobiliary drainage technique. Int J Clin Pharmacol Ther Toxicol 1990; 28(6): 256–261.Search in Google Scholar

31. Kullak-Ublick GA, Becker MB. Regulation of drug and bile salt transporters in liver and intestine. Drug Metab Rev 2003; 35(4): 305–317.10.1081/DMR-12002639814705863Search in Google Scholar

32. Verho M, Luck C, Stelter WJ, Rangoonwala B, Bender N. Pharmacokinetics, metabolism and biliary and urinary excretion of oral ramipril in man. Curr Med Res Opin 1995; 13(5): 264–273.10.1185/030079995091115517555035Search in Google Scholar

33. Ghose AK, Viswanadhan VN, Wendoloski JJ. A Knowledge-Based Approach in Designing Combinatorial or Medicinal Chemistry Libraries for Drug Discovery. J Combin Chem 1999; 1: 55–68.10.1021/cc980007110746014Search in Google Scholar

34. Asuero AG, Sayago A, Gonzalez AG. The correlation coefficient: An overview. Crit Rev Anal Chem 2006; 36: 41-5910.1080/10408340500526766Search in Google Scholar